Sign in
Taking peoplePhase 2

Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder

Key facts

Who runs it
Centre hospitalier de l'Université de Montréal (CHUM)
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
18 Jul 2025
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LDX-01 plus TAU
  • Placebo plus TAU
Record updated
23 February 2026

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Between 18 and 55 years of age at enrollment in the parent ASCME trial
  • Diagnosed with a moderate to severe MUD as defined by the DSM-5 criteria
  • Enrolled in the parent ASCME trial and completed the study up to and including the end of study visit at Week 20, Day 1
  • Interested in avoiding relapse, decreasing methamphetamine use, or abstaining from methamphetamine use
  • Presence of ongoing substance use, craving, or significant risk of relapse that according to the study physician, warrants extended treatment for MUD
  • If female:; Be of non-childbearing potential, defined as (i) postmenopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age); or (ii) documented surgically sterilized (i.e., tubal ligation, hysterectomy, or bilateral oophorectomy); or; Be of childbearing potential, have a negative pregnancy test at screening, and agree to use an acceptable method of birth control throughout the study
  • Willing to be randomized to one of 2 study arms and followed for the duration of the trial
  • Able to start the study intervention within 28 days after completing the ASCME main trial (study no. CRISM-002)
  • Able to provide informed consent
  • Willing to comply with study procedures
  • Able to communicate in English or French

Who cannot take part

  • Planned extended absence during the study period (e.g., pending legal action, surgery, incarceration, inpatient residential program) in the opinion of the study physician that might prevent completion of the study
  • Use of an investigational drug for stimulant use disorder during the 30 days before screening, confirmed via self-report or pharmacy records; excluding the use of study medication in the parent ASCME trial
  • Use of prescribed amphetamine-type medication or medication for the treatment of stimulant use disorder (e.g., methylphenidate, modafinil, bupropion, or mirtazapine) in the 4 weeks before screening
  • Current or anticipated need for treatment with any medication that may interact with LDX-01 (e.g., monoamine oxidase inhibitors [MAOIs]) used currently or within the past 14 days and that would preclude study participant at the discretion of the study physician
  • Symptomatic or advanced cardiovascular disease (e.g., advanced arteriosclerosis), moderate hypertension; confirmed current hyperthyroidism; known hypersensitivity or idiosyncrasy to the sympathomimetic amines or glaucoma or any disabling, severe, or unstable medical condition (including electrolyte disturbances) that, in the opinion of the study physician, precludes safe participation or the ability to provide fully informed consent
  • Any severe or unstable co-morbid substance use disorder that, in the opinion of the study physician, precludes safe participation in the study
  • Participants with Opioid Use Disorder (OUD) who have been on Opioid Agonist Treatment (OAT) for <12 weeks, and not yet at stabilization dose, or at stabilization dose <4 weeks
  • Current or a history of any serious psychiatric disorder (e.g., bipolar disorder, pre-existing psychosis, schizophrenia) that, in the opinion of the study physician, precludes safe participation in the study
  • History of a SAE, hypersensitivity or known allergic reaction to LDX-01 or other amphetamine drugs, or hypersensitivity to the sympathomimetic amines
  • ECG measurement (Bazett method for the correction of QT interval) that indicates a prolonged QTc interval (≥460 milliseconds for females and ≥450 milliseconds for males) at screening
  • Pregnant, nursing, or planning to become pregnant during the study period
  • Any SAEs related to the study product in the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study
  • Any compliance issues related to the study product and/or study procedures during the parent trial phase that, in the opinion of the study physician, precludes safe participation in the extension study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Methamphetamine use disorder (MUD) is becoming an increasing public health concern in Canada. While the evidence on the efficacy and safety of prescription psychostimulants for the treatment of MUD is promising, the knowledge on the maintenance therapy using stimulant agonist therapy is scarce and needs further investigation, especially in terms of long-term retention in treatment.

Read full original descriptionShow less

The goal of this clinical trial is to evaluate the feasibility of a long-term (25 weeks) administration of high-dose stimulant agonist therapy, using Lisdexamfetamine (LDX-01) on top of treatment-as-usual (TAU), in a population of people with moderate to severe MUD, as measured by study retention, treatment retention, treatment adherence and satisfaction compared against a placebo group.

Participants will be placed randomly into one of two groups:

1. TAU and high-dose LDX-01 2. TAU and placebo

The 2 groups in the trial

  • LDX-01 + TAUTreatment being tested

    Participants will receive TAU at the clinic as well as once daily over-encapsulated LDX-01 orally for 25 weeks.

    Treatment: LDX-01 plus TAU

  • Placebo + TAUPlacebo, for comparison

    Participants will receive TAU at the clinic as well as once daily LDX-01-matched placebo orally for 25 weeks.

    Treatment: Placebo plus TAU

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Exploring Feasibility and Acceptability of Prolonged Administration of High-Dose Stimulants in People With Methamphetamine Use Disorder: An Extension of a Randomized, Placebo-Controlled Trial
Fit questions
Built from NCT06788587, who can take part
Record updated
23 February 2026